Skip to main content

Read an important notice regarding the data security incident McKesson reported on August 28, 2026. Read more.

Clinical Trials

BRCC Research Institute 2026

< All Clinical Trials

Luspatercept vs. Epoetin Alfa for the treatment of Anemia due to Low-Risk MDS

Disease Type: Hematology

A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) vs Epoetin Alfa for the Treatment of Anemia Due to Revised International Prognostic Scoring System (IPSS-R) Very Low, Low, or Intermediate-Risk Myelodysplastic Syndrome (MDS) in Erythropoiesis-Stimulating Agent (ESA)-naive Participants who are Non-Transfusion Dependent (NTD): The “ELEMENT-MDS” Trial

Locations

Alleghany , Blacksburg , Roanoke , Salem , Wytheville

View on ClinicalTrials.gov